Why the study?
Does 3-month adjunctive celecoxib reduce late loss of drug-eluting stents in patients with angina undergoing coronary intervention?
Population
Patients with angina undergoing coronary intervention with drug-eluting stents and receiving dual…
Design
RCT
Follow-up
3 months
Authors
Loading...
Should not change DES practice; leaves open net benefit of celecoxib on late loss versus thrombosis in RCTs.
Does 3-month adjunctive celecoxib reduce late loss of drug-eluting stents in patients with angina undergoing coronary intervention?
While 3-month adjunctive celecoxib reduces late loss in drug-eluting stents, it may increase thrombotic risk despite concurrent dual antiplatelet therapy.
Kang et al. (2012) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: